ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.00 Average Price Target from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus recommendation of “Buy” by the four analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the stock in the last year is $80.00.

A number of brokerages recently commented on ANIP. Capital One Financial began coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright lifted their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Guggenheim reiterated a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Finally, Truist Financial lifted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $68.05 on Friday. The company has a market cap of $1.43 billion, a PE ratio of 81.01 and a beta of 0.80. The stock’s 50 day simple moving average is $66.94 and its 200-day simple moving average is $59.48. ANI Pharmaceuticals has a 1-year low of $38.91 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 3.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the completion of the sale, the senior vice president now owns 233,226 shares of the company’s stock, valued at $15,537,516.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $65.35, for a total value of $659,577.55. Following the completion of the sale, the chief operating officer now directly owns 872,527 shares of the company’s stock, valued at $57,019,639.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the sale, the senior vice president now directly owns 233,226 shares of the company’s stock, valued at $15,537,516.12. The disclosure for this sale can be found here. Insiders sold a total of 176,803 shares of company stock valued at $11,695,866 over the last quarter. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Global Alpha Capital Management Ltd. grew its stake in shares of ANI Pharmaceuticals by 15.9% in the third quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company’s stock valued at $30,512,000 after buying an additional 72,200 shares in the last quarter. ClariVest Asset Management LLC grew its stake in shares of ANI Pharmaceuticals by 36.7% in the third quarter. ClariVest Asset Management LLC now owns 51,338 shares of the specialty pharmaceutical company’s stock valued at $2,980,000 after buying an additional 13,792 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of ANI Pharmaceuticals by 287.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after buying an additional 109,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $685,000. Finally, EAM Investors LLC purchased a new position in ANI Pharmaceuticals in the third quarter valued at $1,489,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.